Serum Anti-Mullerian Hormone Levels Might Indicate Premenopausal Endometrial Lesions

被引:0
作者
Yao, Yingsha [1 ]
Shi, Liujing [1 ]
Zhu, Xiaoming [1 ,2 ]
机构
[1] Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou 310006, Peoples R China
[2] Zhejiang Univ, Womens Hosp, Sch Med, Key Lab Womens Reprod Hlth Zhejiang Prov, Hangzhou 310006, Peoples R China
关键词
polycystic ovary syndrome; endometrial proliferative lesions; anti-Mullerian hormone; threshold value; regression model; POLYCYSTIC-OVARY-SYNDROME; CANCER STATISTICS; RISK; HYPERPLASIA; ULTRASOUND; PREDICTION; CONSENSUS; CRITERIA; CA125; HE-4;
D O I
10.3390/diagnostics13213301
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Endometrial proliferative lesions (EPL) usually refer to endometrial hyperplasia (EH) and endometrial cancer (EC). Among patients with premenopausal EPL who wish to preserve their fertility, only those with EH and early-stage EC have the possibility to undergo fertility preservation therapy. However, there is currently a lack of specific and reliable screening criteria and models for identifying these patients. Methods: This study utilized a retrospective diagnostic study design. The training set included medical record information that met the criteria between August 2017 and October 2022, while the validation set consisted of medical record information that met the criteria from November 2022 to May 2023. The endometrial pathological test served as the gold standard. The serum anti-Mullerian hormone (AMH) level before endometrial sampling and a regression model were employed to predict EPL. Results: The study included a total of 1209 patients with PCOS (1119 in the control group and 90 in the endometrial proliferative lesion group) and 5366 women without PCOS (5249 in the control group and 117 in the proliferative lesion group). In the case of PCOS patients aged 20-39 years, the most effective screening threshold for AMH was found to be a serum AMH level of <= 5.39 ng/mL. The model used for this group was logit(p) = -2.562 - 0.430 x AMH + 0.127 x BMI + 1.512 x hypertension + 0.956 x diabetes -1.145 x regular menstruation. On the other hand, for non-PCOS women aged 20-39 years, the optimal screening threshold for AMH was determined to be a serum AMH value of <= 2.18 ng/mL. The model used for this group was logit(p) = -3.778 - 0.823 x AMH + 0.176 x BMI + 2.660 x diabetes -1.527 x regular menstruation -1.117 x dysmenorrhea. It is important to note that all of these findings have successfully passed internal verification. Conclusion: For PCOS and non-PCOS women aged 20-39 years, the serum AMH test and related multiple regression models were obtained for the warning of EPL.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Anti-Mullerian hormone levels in American girls by age and race/ethnicity
    Elchuri, Swati V.
    Patterson, Briana C.
    Brown, Milton R.
    Buchanan, Iris
    Mertens, Ann C.
    Meacham, Lillian R.
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2015, 28 (1-2) : 189 - 193
  • [32] Anti-Mullerian hormone levels and risk of type 2 diabetes in women
    Verdiesen, Renee M. G.
    Onland-Moret, N. Charlotte
    van Gils, Carla H.
    Stellato, Rebecca K.
    Spijkerman, Annemieke M. W.
    Picavet, H. Susan J.
    Broekmans, Frank J. M.
    Verschuren, W. M. Monique
    van der Schouw, Yvonne T.
    DIABETOLOGIA, 2021, 64 (02) : 375 - 384
  • [33] Serum anti-Mullerian hormone in subfertile women
    Somigliana, Edgardo
    Lattuada, Debora
    Colciaghi, Barbara
    Filippi, Francesca
    La Vecchia, Irene
    Tirelli, Amedea
    Baffero, Giulia M.
    Paffoni, Alessio
    Persico, Nicola
    Bolis, Giorgio
    Fedele, Luigi
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2015, 94 (12) : 1307 - 1312
  • [34] The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study
    Homburg, R.
    Ray, A.
    Bhide, P.
    Gudi, A.
    Shah, A.
    Timms, P.
    Grayson, K.
    HUMAN REPRODUCTION, 2013, 28 (04) : 1077 - 1083
  • [35] Determination of Ovarian Reserve with Anti-Mullerian Hormone in Patients with Polycystic Ovary Syndrome and Premenopausal Women
    Inan, Cihan
    Yucel, Nese
    Isbilen, Banu
    Isman, Kemal Ferruh
    Bilgic, Ergun
    Ozer, Atinc
    JOURNAL OF ACADEMIC RESEARCH IN MEDICINE-JAREM, 2014, 4 (02): : 62 - 68
  • [36] Serum anti-mullerian hormone, sex hormone, and nutrient levels in reproductive age women with celiac disease
    Tuerxuntayi, Ailifeire
    Shi, Tian
    Gao, Beiyao
    Feng, Yan
    Li, Ting
    Hui, Wenjia
    Xue, Shenglong
    Gao, Feng
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2024, 41 (08) : 2129 - 2136
  • [37] The effect of different hormone therapies on anti-mullerian hormone serum levels in anovulatory women of reproductive age
    Fabregues, Francisco
    Castelo-Branco, Camil
    Carmona, Francisco
    Guimera, Marta
    Casamitjana, Roser
    Balasch, Juan
    GYNECOLOGICAL ENDOCRINOLOGY, 2011, 27 (04) : 216 - 224
  • [38] Anti-Mullerian Hormone Concentrations Are Inversely Associated With Subclinical Atherosclerosis in Premenopausal Women
    Lambrinoudaki, Irene
    Stergiotis, Stefanos
    Chatzivasileiou, Panagiota
    Augoulea, Areti
    Anagnostis, Panagiotis
    Armeni, Eleni
    Rizos, Dimitrios
    Kaparos, George
    Alexandrou, Andreas
    Georgiopoulos, Georgios
    Kontogiannis, Christos
    Stamatelopoulos, Kimon
    ANGIOLOGY, 2020, 71 (06) : 552 - 558
  • [39] Anti-Mullerian hormone levels in girls and adolescents
    Czech, Iwona J.
    Drosdzol-Cop, Agnieszka
    GINEKOLOGIA POLSKA, 2022, 93 (09) : 756 - 760
  • [40] Anti-Mullerian hormone and endometrial cancer: a multi-cohort study
    Fortner, Renee T.
    Schock, Helena
    Jung, Seungyoun
    Allen, Naomi E.
    Arslan, Alan A.
    Brinton, Louise A.
    Egleston, Brian L.
    Falk, Roni T.
    Gunter, Marc J.
    Helzlsouer, Kathy J.
    Idahl, Annika
    Johnson, Theron S.
    Kaaks, Rudolf
    Krogh, Vittorio
    Lundin, Eva
    Merritt, Melissa A.
    Navarro, Carmen
    Onland-Moret, N. Charlotte
    Palli, Domenico
    Shu, Xiao-Ou
    Sluss, Patrick M.
    Staats, Paul N.
    Trichopoulou, Antonia
    Weiderpass, Elisabete
    Zeleniuch-Jacquotte, Anne
    Zheng, Wei
    Dorgan, Joanne F.
    BRITISH JOURNAL OF CANCER, 2017, 117 (09) : 1412 - 1418